About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01130259

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

Update: This study is no longer recruiting patients.

Study identifier: NCT01130259
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Iniparib (Sanofi Aventis)

Eligibility:

• Histologically documented triple negative breast cancer
• One to three prior chemotherapy regimens in the metastatic setting
• Metastatic breast cancer (Stage IV)
• Enrollment is limited and will be determined by a validated Random-Selection Process administered by NORD (National Organization of Rare Disorders).

Type of study:

Phase III study

Treatment:

Patients will receive gemcitabine and carboplatin with our without iniparib.

Study sites:

Update: This study is no longer recruiting patients.

Page updated 06/13/13    


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org